Intellia Therapeutics, Inc. (0JBU.L)
USD 12.59
(-6.07%)
USD 12.59
(-6.07%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -506.31 Million USD | -13.84% |
| 2022 | -450.59 Million USD | -66.02% |
| 2021 | -260.95 Million USD | -96.11% |
| 2020 | -130.27 Million USD | -35.52% |
| 2019 | -100.78 Million USD | -10.91% |
| 2018 | -86.4 Million USD | -30.64% |
| 2017 | -66.56 Million USD | -116.28% |
| 2016 | -31.05 Million USD | -145.85% |
| 2015 | -13.08 Million USD | -150.52% |
| 2014 | -9.53 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -111.49 Million USD | 18.87% |
| 2024 Q2 | -136.44 Million USD | -22.38% |
| 2023 Q2 | -132.33 Million USD | -18.31% |
| 2023 FY | - USD | -13.84% |
| 2023 Q4 | -137.42 Million USD | -4.82% |
| 2023 Q1 | -111.85 Million USD | -6.88% |
| 2023 Q3 | -131.1 Million USD | 0.93% |
| 2022 Q1 | -142.07 Million USD | -76.67% |
| 2022 Q4 | -104.66 Million USD | -9.28% |
| 2022 Q3 | -95.77 Million USD | 2.74% |
| 2022 Q2 | -98.47 Million USD | 30.69% |
| 2022 FY | - USD | -66.02% |
| 2021 Q3 | -70.2 Million USD | -4.19% |
| 2021 Q4 | -80.41 Million USD | -14.54% |
| 2021 FY | - USD | -96.11% |
| 2021 Q1 | -44.83 Million USD | -5.74% |
| 2021 Q2 | -67.38 Million USD | -50.29% |
| 2020 Q4 | -42.39 Million USD | -60.0% |
| 2020 FY | - USD | -35.52% |
| 2020 Q1 | -31.5 Million USD | -11.77% |
| 2020 Q3 | -26.5 Million USD | 15.79% |
| 2020 Q2 | -31.46 Million USD | 0.12% |
| 2019 Q3 | -23.94 Million USD | 8.39% |
| 2019 FY | - USD | -10.91% |
| 2019 Q1 | -22.51 Million USD | -8.5% |
| 2019 Q4 | -28.18 Million USD | -17.72% |
| 2019 Q2 | -26.13 Million USD | -16.12% |
| 2018 Q4 | -20.74 Million USD | 9.59% |
| 2018 FY | - USD | -30.64% |
| 2018 Q3 | -22.94 Million USD | -1.89% |
| 2018 Q2 | -22.52 Million USD | -5.15% |
| 2018 Q1 | -21.41 Million USD | 13.34% |
| 2017 FY | - USD | -116.28% |
| 2017 Q3 | -15.08 Million USD | 1.44% |
| 2017 Q2 | -15.3 Million USD | -24.56% |
| 2017 Q4 | -24.71 Million USD | -63.84% |
| 2017 Q1 | -12.28 Million USD | -13.55% |
| 2016 FY | - USD | -145.85% |
| 2016 Q4 | -10.82 Million USD | -45.61% |
| 2016 Q3 | -7.43 Million USD | -10.94% |
| 2016 Q2 | -6.69 Million USD | -2.95% |
| 2016 Q1 | -6.5 Million USD | -21.42% |
| 2015 FY | - USD | -150.52% |
| 2015 Q3 | -3.2 Million USD | 4.47% |
| 2015 Q4 | -5.35 Million USD | -67.21% |
| 2015 Q1 | -1.16 Million USD | 72.25% |
| 2015 Q2 | -3.35 Million USD | -188.73% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | -4.18 Million USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | -210.4% |
| Dynavax Technologies Corporation | 9.66 Million USD | 5338.103% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 615.27% |
| Perrigo Company plc | 646.2 Million USD | 178.353% |
| Illumina, Inc. | -608 Million USD | 16.725% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 104.688% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | -12.762% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 95.511% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 115.55% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -387.817% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 110.879% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -1258.032% |
| Waters Corporation | 1.02 Billion USD | 149.529% |
| Biogen Inc. | 2.37 Billion USD | 121.301% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -479.129% |
| Evolus, Inc. | -41.81 Million USD | -1110.99% |
| Adicet Bio, Inc. | -136.53 Million USD | -270.832% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -330.357% |
| bluebird bio, Inc. | -167.16 Million USD | -202.891% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -237.3% |
| FibroGen, Inc. | -261.4 Million USD | -93.69% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 130.192% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -1039.407% |
| Homology Medicines, Inc. | -47.75 Million USD | -960.212% |
| Geron Corporation | -174.78 Million USD | -189.684% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | -121.95% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -449.87% |
| Myriad Genetics, Inc. | -67.8 Million USD | -646.777% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -402.162% |
| Zoetis Inc. | 3.68 Billion USD | 113.74% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -901.177% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 143.496% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 263.178% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 110.994% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -1303.234% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | -120.127% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | -90.346% |
| Verastem, Inc. | -83.16 Million USD | -508.8% |
| Nektar Therapeutics | -243.1 Million USD | -108.268% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -125.038% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -475.456% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | -15.282% |
| OPKO Health, Inc. | -65.51 Million USD | -672.811% |
| Exelixis, Inc. | 196.6 Million USD | 357.533% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 221.681% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 567.408% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -808.091% |
| uniQure N.V. | -253.1 Million USD | -100.045% |
| Imunon, Inc. | -20.78 Million USD | -2336.283% |
| Blueprint Medicines Corporation | -474.61 Million USD | -6.68% |
| Insmed Incorporated | -654.73 Million USD | 22.669% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 212.03% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | -46.56% |
| TG Therapeutics, Inc. | 26.1 Million USD | 2039.904% |
| Incyte Corporation | 919.42 Million USD | 155.069% |
| Emergent BioSolutions Inc. | -505.29 Million USD | -0.201% |